Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.